Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate Approves FDA User Fee Reauthorization Bill On 94-1 Vote

Executive Summary

The Senate Aug. 3 swiftly approved the FDA Reauthorization Act (FDARA) on a 94-1 vote. The president is expected to sign the bill, which previously passed the House and will enact the MDUFA IV user-fee agreement and make reforms tied to device accessory review, device facility inspections, and medical imaging FDA reviews.


Related Content

Medtech-Supporter Sen. Al Franken To Resign, After Harassment Charges
MDUFA IV (And More) Is Law: Trump Signs A Health-Care Bill
'It's Time': AdvaMed Device Tax Ad Campaign Sets Sights On Key Lawmakers
Hiring Plans Are Central To US FDA's Digital Health Plan
Senate Expected To Vote On US FDA User-Fee Bill August 3
Capitol Hill Update: Congress Gets Reprieve On User Fee Passage, While AdvaMed Weighs Device Tax Options
White House Continues To Push For Higher User Fees From Industry
US FDA User-Fee Bill Swiftly Passes US House, Now Moves To Senate
House Committee Advances User Fees With Full Slate Of Device Amendments
User-Fee Facts: 10 Key Medtech Details From US FDA Agreements


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts